SBL
TCRT icon

Sargent Bickham Lagudis’s Alaunos Therapeutics TCRT Stock Holding History

Sargent Bickham Lagudis’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed -$1K – 1008
2021
Q3 		$1K Hold
2
– – ﹤0.01% 924
2021
Q2 		$1K Hold
2
– – ﹤0.01% 903
2021
Q1 		$1K Hold
2
– – ﹤0.01% 906
2020
Q4 		$1K Buy
+2
New +$795 ﹤0.01% 846

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sargent Bickham Lagudis's TCRT Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 2 shares — an estimated $1K sold.

Sargent Bickham Lagudis first reported a position in TCRT in Q4 2020 and held it in 4 quarters. The position peaked at $1K in Q3 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Sargent Bickham Lagudis reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 2 Alaunos Therapeutics shares in Q4 2021, an estimated $1K.
  • Sargent Bickham Lagudis first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 4 quarters.
  • Sargent Bickham Lagudis's Alaunos Therapeutics position peaked at $1K in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.